Emergent BioSolutions (EBS) vs Galectin Therapeutics (GALT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Galectin Therapeutics (GALT) has outperformed Emergent BioSolutions (EBS) over the past year, losing 24.1% versus a loss of 28.7%. Over five years, GALT leads with a +7.4% price change compared with -86.1% for EBS. Galectin Therapeutics is the larger company by market cap ($365.1 million vs $362.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EBS | GALT |
|---|---|---|
| Share price | $7.07 | $3.62 |
| Market cap | $362.50M | $365.08M |
| 1-day change | +1.73% | -3.72% |
| YTD return | -42.80% | -12.98% |
| 1-year return | -28.73% | -24.11% |
| 5-year return | -86.05% | +7.42% |
| Forward P/E | 6.76 | — |
| EPS (TTM) | $-3.40 | $-0.43 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.06 | $7.13 |
| 52-week low | $4.36 | $2.03 |
| Distance from 52-week high | -49.72% | -49.23% |
| Analyst consensus | none | none |
| Avg. price target upside | +55.59% | +203.87% |
| Average volume | 1.16M | 387.94K |
| Shares outstanding | 51.27M | 100.85M |
| Employees | 900 | 9 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Emergent BioSolutions
EBS stock →Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 900 employees
About Galectin Therapeutics
GALT stock →Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension.
Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees
EBS vs GALT FAQ
Which is bigger, Emergent BioSolutions or Galectin Therapeutics?
Galectin Therapeutics (GALT) is larger, with a market capitalization of $365.08M compared with $362.50M for Emergent BioSolutions (EBS).
Which stock has performed better over the past year, EBS or GALT?
GALT returned -24.11% over the past 12 months, compared with -28.73% for EBS (price return, excluding dividends). Past performance does not predict future results.
Are Emergent BioSolutions and Galectin Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.